Sign In
Buy PFE
$25.69
+0.335 (+1.32%)
At Close: Jun 04, 2026
3 Dividend Stocks to Buy and Hold for the Next Decade
07:47am, Monday, 28'th Apr 2025
Many income investors would love to have a low-maintenance portfolio that doesn't require constant attention. They'd prefer to buy great stocks and rake in the dividends without any hiccups.
My 5 Top Stocks to Buy Right Now in This Highly Volatile Market
04:48am, Monday, 28'th Apr 2025
Getting dizzy from the stock market's gyrations? Join the club.
Pfizer: I Am Locking In A 7.5% Dividend Yield Before Earnings
06:11am, Sunday, 27'th Apr 2025
Pfizer's Q1 earnings release is a prime opportunity to secure about a 7.55% dividend yield, with revenue stabilizing post-pandemic and strong cost efficiency. Pfizer's robust product pipeline and cons
Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
01:30pm, Saturday, 26'th Apr 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination wi
3 High Yield Dividend Stocks Under $25 to Buy and Hold Forever
09:30am, Friday, 25'th Apr 2025
As income and wealth inequality continue to divide Americans into two distinct classes and levels of wealth, those who are struggling to find investments that can outpace inflation and the growing cos
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season?
08:10am, Friday, 25'th Apr 2025
Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.
Prediction: 1 Biotech Stock That Could Surpass Pfizer by 2030
01:14pm, Thursday, 24'th Apr 2025
Pfizer (PFE) has been a behemoth in pharmaceuticals and drug development for decades, but lately has run into headwinds from vaccine sales, patent expiry, and more.
PFE vs. LLY: Which Stock Should Value Investors Buy Now?
12:40pm, Thursday, 24'th Apr 2025
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Pfizer (PFE) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?
Are Investors Undervaluing Pfizer (PFE) Right Now?
10:45am, Thursday, 24'th Apr 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Curious about Pfizer (PFE) Q1 Performance? Explore Wall Street Estimates for Key Metrics
10:20am, Thursday, 24'th Apr 2025
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Pfizer (PFE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quar
5 All-Weather Dividend Stocks to Buy Right Now
08:30am, Thursday, 24'th Apr 2025
Market uncertainty has become the defining characteristic of the 2025 investment landscape. Thanks to volatile trade policies, persistent inflation concerns, and geopolitical tensions, investors are f
2 No-Brainer Stocks to Buy With Less Than $30
06:45am, Thursday, 24'th Apr 2025
Having significant capital in the bank when investing in equities is helpful, but is by no means necessary. Even with a relatively modest sum, like $30, it's possible to acquire one whole share of a t
Should You Buy the 3 Highest-Paying Dividend Stocks in the S&P 500?
04:51am, Thursday, 24'th Apr 2025
Going against the grain often works in investing. Several of the most successful investors are contrarians by nature.
Pfizer Declares Second-Quarter 2025 Dividend
04:40pm, Wednesday, 23'rd Apr 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company's common stock, payable June 13, 2025, to ho
Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
03:46pm, Wednesday, 23'rd Apr 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO®) Annual
